Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

UCSB discovery may accelerate new treatment for global health problem

25.02.2004


The University of California, Santa Barbara announced today that it has donated all rights to a patent that covers the novel use of an established class of cardiovascular medicines as a potential new drug against a global parasitic disease. The Institute for OneWorld Health, a nonprofit pharmaceutical company based in San Francisco, will use the UCSB discovery and the wealth of data associated with the medicines to accelerate drug development for treatment of schistosomiasis.



Two UCSB researchers discovered that calcium channel blockers may prove to be an inexpensive alternative for controlling schistosome infection, a serious global health problem that afflicts more than 200 million people annually in developing nations. An estimated 200,000 people, many of them older children, die every year from schistosomiasis. Many more suffer chronic damage to vital organs, including the liver and bladder.

The inventors are Mark Walter, a research biologist, and Armand Kuris, professor of biology. "Calcium channel blockers look very promising for the treatment of schistosomiasis, which is a devastating disease," said Kuris, an expert in parasitology and associate provost of the College of Creative Studies. Physicians routinely prescribe calcium channel blockers to treat high blood pressure, correct abnormal heart rhythms, treat panic attacks and bipolar disorder, and prevent migraine headaches.


"We know that the drugs are safe for people," said Kuris. "They are available, and not terribly expensive. For a tropical disease that is very, very important. We are gratified by OneWorld Health’s interest in our discovery, and confident in its ability to develop this inexpensive treatment for schistosomiasis for children in rural villages throughout the world."

OneWorld Health partners with pharmaceutical and biotechnology companies, universities, government agencies, and global health advocates to develop compounds or medicines that exhibit promise in treating developing world diseases. Its strategy is to secure intellectual property rights to innovations that might not otherwise be developed.

"The generous donation of this UCSB patent is a sterling model for other academic and biopharmaceutical organizations seeking to contribute to global health," said Victoria G. Hale, CEO of OneWorld Health. "We are excited at the prospect of creating a new use for these drugs. Their well-documented safety and effectiveness could reduce the number of years it might take to bring a new treatment to people with schistosomiasis." Hale is an expert in the treatment of tropical infectious diseases and drug development, and has had experience at the Food and Drug Administration and Genentech.

About Schistosomiasis

For more than 30 years, scientists have attempted to develop a vaccine against schistosomiasis with no success. The parasitic flatworm infects more than 200 million people worldwide, with three times that many individuals at risk for infection.

Although the schistosome life cycle also involves an invertebrate host, the parasite is not transmitted through the bite of an insect, but rather develops within freshwater snails. After exiting from the snail vector, schistosome larvae swim along until they contact a human host bathing or working in the water. They penetrate the skin and subsequently migrate through the blood vessels until finally establishing residence in veins of the intestines or urinary bladder. The adult male and female worms pair, mate, and produce large numbers of eggs, some of which are excreted in either feces or urine and end up in the water supply, where they hatch and complete the cycle by infecting new snail hosts. Those eggs that are not excreted become trapped in the tissues of the liver, spleen, intestine and bladder, where they become calcified. Over time the accumulation of thousands of eggs causes severe and irreversible damage to these organs.

A number of existing drugs treat schistosomiasis by killing the adult worms, but side effects can occur and none of the treatments provides lasting immunity. In fact, reinfection after anti-schistosomal drug treatment is fairly common, according to the researchers, because people return to infected water sources. The widespread and repeated treatment of people with these drugs has also resulted in the appearance of drug resistant strains of schistosomes. Moreover, the cost of drug treatment is beyond the reach of many Asian, African, and Latin American countries.

Mark Walter decided to attack schistosomiasis by attacking the ability of the worm to produce eggs. By investigating the physiology of schistosome egg production, Walter and Kuris found that these parasites may need calcium to reproduce. They discovered that calcium channel blockers, medicines that slow the movement of calcium into the cells, suppressed the production of eggs by the schistosomes when tested in vitro. The researchers explained that if schistosome egg production in humans could be suppressed by this type of treatment, then both the pathology of the disease and the continuation of the parasite lifecycle could be halted. The presence of the nonreproductive worms may also help infected people keep their immunity to reinfection.


The Institute for OneWorld Health, a nonprofit pharmaceutical company, advances global health by developing new, affordable medicines for infectious diseases that disproportionately affect people in the developing world. OneWorld Health accomplishes this through an entrepreneurial business model in which its staff of experienced pharmaceutical scientists identifies promising drug leads and drives their development from pre-clinical studies to clinical trials through regulatory approval. The Institute for OneWorld Health, headquartered in San Francisco, is a tax-exempt 501(c)(3), U.S. corporation.

Note to Editors: For more information about this discovery, please contact Mark Walter at (805) 637-7052, e-mail: walter@lifesci.ucsb.edu or Armand Kuris at (805) 965-0931 or 893-3998, e-mail: kuris@lifesci.ucsb.edu

Paul Desruisseaux | EurekAlert!
Further information:
http:// www.oneworldhealth.org
http://www.ucsb.edu/

More articles from Health and Medicine:

nachricht Organ-on-a-chip mimics heart's biomechanical properties
23.02.2017 | Vanderbilt University

nachricht Researchers identify cause of hereditary skeletal muscle disorder
22.02.2017 | Klinikum der Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Safe glide at total engine failure with ELA-inside

On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded after a glide flight with an Airbus A320 in ditching on the Hudson River. All 155 people on board were saved.

On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded...

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

Safe glide at total engine failure with ELA-inside

27.02.2017 | Information Technology

Fraunhofer IFAM expands its R&D work on Coatings for protection against corrosion and marine growth

27.02.2017 | Materials Sciences

Stingless bees have their nests protected by soldiers

24.02.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>